These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38423787)

  • 21. [
    Peters SMB; Hofferber R; Privé BM; de Bakker M; Gotthardt M; Janssen M; de Lange F; Muselaers CHJ; Mehra N; Witjes JA; Costa PF; Nagarajah J; Konijnenberg MW; Jentzen W
    Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1101-1112. PubMed ID: 34623453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimation of [177Lu]PSMA-617 tumor uptake based on voxel-wise 3D Monte Carlo tumor dosimetry in patients with metastasized castration resistant prostate cancer.
    Götz TI; Lang EW; Prante O; Cordes M; Kuwert T; Ritt P; Ludwig B; Schmidkonz C
    Nuklearmedizin; 2020 Sep; 59(5):365-374. PubMed ID: 32663888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biodistribution and dosimetry for combined [
    Delker A; Schleske M; Liubchenko G; Berg I; Zacherl MJ; Brendel M; Gildehaus FJ; Rumiantcev M; Resch S; Hürkamp K; Wenter V; Unterrainer LM; Bartenstein P; Ziegler SI; Beyer L; Böning G
    Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1280-1290. PubMed ID: 36629878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [
    Schaefer-Schuler A; Burgard C; Blickle A; Maus S; Petrescu C; Petto S; Bartholomä M; Stemler T; Ezziddin S; Rosar F
    Theranostics; 2024; 14(5):1829-1840. PubMed ID: 38505615
    [No Abstract]   [Full Text] [Related]  

  • 25. Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resistant Prostate Carcinoma.
    Khawar A; Eppard E; Sinnes JP; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
    Clin Nucl Med; 2018 Jul; 43(7):486-491. PubMed ID: 29688951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimation of kidney doses from [
    Spink S; Gillett D; Heard S; Harper I; Casey R; Aloj L
    EJNMMI Phys; 2024 Jul; 11(1):68. PubMed ID: 39052172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
    Baum RP; Kulkarni HR; Schuchardt C; Singh A; Wirtz M; Wiessalla S; Schottelius M; Mueller D; Klette I; Wester HJ
    J Nucl Med; 2016 Jul; 57(7):1006-13. PubMed ID: 26795286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.
    Delker A; Fendler WP; Kratochwil C; Brunegraf A; Gosewisch A; Gildehaus FJ; Tritschler S; Stief CG; Kopka K; Haberkorn U; Bartenstein P; Böning G
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):42-51. PubMed ID: 26318602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First-Strike Rapid Predictive Dosimetry and Dose Response for
    Kao YH; Falzone N; Pearson M; Sivaratnam D
    J Nucl Med Technol; 2024 Sep; 52(3):212-218. PubMed ID: 38901967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single-Time-Point Imaging for Dosimetry After [
    Wang C; Peterson AB; Wong KK; Roseland ME; Schipper MJ; Dewaraja YK
    J Nucl Med; 2023 Sep; 64(9):1463-1470. PubMed ID: 37500260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of
    Pathmanandavel S; Crumbaker M; Ho B; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Hickey A; Eu P; Stockler M; Martin AJ; Joshua AM; Nguyen A; Emmett L
    J Nucl Med; 2023 Feb; 64(2):221-226. PubMed ID: 36008120
    [No Abstract]   [Full Text] [Related]  

  • 32. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
    Sartor O; de Bono J; Chi KN; Fizazi K; Herrmann K; Rahbar K; Tagawa ST; Nordquist LT; Vaishampayan N; El-Haddad G; Park CH; Beer TM; Armour A; Pérez-Contreras WJ; DeSilvio M; Kpamegan E; Gericke G; Messmann RA; Morris MJ; Krause BJ;
    N Engl J Med; 2021 Sep; 385(12):1091-1103. PubMed ID: 34161051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A population-based method to determine the time-integrated activity in molecular radiotherapy.
    Hardiansyah D; Riana A; Kletting P; Zaid NRR; Eiber M; Pawiro SA; Beer AJ; Glatting G
    EJNMMI Phys; 2021 Dec; 8(1):82. PubMed ID: 34905131
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection.
    Yadav S; Jiang F; Kurkowska S; Saelee R; Morley A; Feng F; Aggarwal R; Lawhn-Heath C; Uribe C; Hope TA
    J Nucl Med; 2024 Jul; 65(7):1064-1069. PubMed ID: 38724282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of
    Violet J; Sandhu S; Iravani A; Ferdinandus J; Thang SP; Kong G; Kumar AR; Akhurst T; Pattison DA; Beaulieu A; Mooi J; Tran B; Guo C; Kalff V; Murphy DG; Jackson P; Eu P; Scalzo M; Williams S; Hicks RJ; Hofman MS
    J Nucl Med; 2020 Jun; 61(6):857-865. PubMed ID: 31732676
    [No Abstract]   [Full Text] [Related]  

  • 36. [
    Graef J; Bluemel S; Brenner W; Amthauer H; Truckenmueller P; Kaul D; Vajkoczy P; Onken JS; Furth C
    J Nucl Med; 2023 Jun; 64(6):892-895. PubMed ID: 37116918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase 1 trial to determine the maximum tolerated dose and patient-specific dosimetry of [
    Zang J; Wang G; Zhao T; Liu H; Lin X; Yang Y; Shao Z; Wang C; Chen H; Chen Y; Zhu Z; Miao W; Chen X; Zhang J
    Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):871-882. PubMed ID: 37864592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dosimetric Analysis of a Phase I Study of PSMA-Targeting Radiopharmaceutical Therapy With [
    Ha S; O JH; Park C; Boo SH; Yoo IR; Moon HW; Chi DY; Lee JY
    Korean J Radiol; 2024 Feb; 25(2):179-188. PubMed ID: 38288897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Translation and First In-Human Use of [
    Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
    Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Experience with [
    Alan-Selcuk N; Beydagi G; Demirci E; Ocak M; Celik S; Oven BB; Toklu T; Karaaslan I; Akcay K; Sonmez O; Kabasakal L
    J Nucl Med; 2023 Oct; 64(10):1574-1580. PubMed ID: 37620050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.